title: Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy.
abstract: Blocking IL-1 in patients with knee osteoarthritis is an attractive strategy. Cohen and colleagues report a randomised, placebo-controlled, multiple-dose trial using a monoclonal antibody blocking IL-1 type 1 receptor. They failed to show any positive results in terms of evolution of pain for up to 12 weeks, in line with the former trials using intraarticular injections of IL-1 receptor antagonist. A trend was observed, however, in a subgroup of patients with high level of pain at baseline. Although these data may suggest cessation of IL-1 therapy in osteoarthritis, other methods such as limited intraarticular anti-IL-1 delivery should still be considered.
authors: Department of Rheumatology, University of Paris XII, Henri Mondor Hospital, Bd de Lattre de Tassigny, Creteil 94010, France. xavier.chevalier@hmn.aphp.fr
authors: Xavier
authors: X
authors: Chevalier
authors: Thierry
authors: T
authors: Conrozier
authors: Pascal
authors: P
authors: Richette
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors*; D010003:Osteoarthritis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic
chemical_list: C557018:AMG 108; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007375:Interleukin-1